Who has been buying Femtobiomed stock?

1 distinct insiders have filed 14 disclosed insider purchases in Femtobiomed (327610), most recently on 2025-11-05. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.

How many insider filings does Femtobiomed have?

Femtobiomed has 14 buy-side and 0 sell-side disclosures on record, covering ₩36M ($25K) in total reported value, spanning 2021-07-27 to 2025-11-05.

Do insider buys in Korean stocks predict returns?

Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Femtobiomed 327610

Company

펨토바이오메드Femtobiomed

Insiders

Buys

Total Value

₩36M ($25K)

Avg Return

-81.83%

Last Filing

2025-11-05

Femtobiomed (327610) has 14 disclosed insider purchases and 0 disclosed disposals on record, filed by 1 distinct insiders. Together those filings cover ₩36M ($25K) in reported transaction value. The earliest filing StockDrifts holds for Femtobiomed is dated 2021-07-27; the most recent is 2025-11-05. Across these filings the average return since disclosure is -81.83%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

Date	Type	Source	Insider	Position	Shares	Price at filing	Return	Value
2025-11-05	BUY	장외매수	이상현 Sanghyun Lee	CEO	20.7K	₩2,045	-48.9%	₩42M ($29K)
2025-06-17	BUY	Market Buy	이상현 Sanghyun Lee	CEO	334	₩5,380	-80.6%	₩2M ($1K)
2025-06-16	BUY	Market Buy	이상현 Sanghyun Lee	CEO	100	₩5,780	-81.9%	₩578K ($401)
2025-06-13	BUY	Market Buy	이상현 Sanghyun Lee	CEO	200	₩5,690	-81.6%	₩1M ($790)
2025-06-12	BUY	Market Buy	이상현 Sanghyun Lee	CEO	200	₩6,000	-82.6%	₩1M ($833)
2025-06-11	BUY	Market Buy	이상현 Sanghyun Lee	CEO	200	₩5,290	-80.3%	₩1M ($735)
2025-06-10	BUY	Market Buy	이상현 Sanghyun Lee	CEO	300	₩4,600	-77.3%	₩1M ($958)
2025-06-09	BUY	Market Buy	이상현 Sanghyun Lee	CEO	700	₩4,000	-73.9%	₩3M ($2K)
2025-06-05	BUY	Market Buy	이상현 Sanghyun Lee	CEO	2.9K	₩3,910	-73.3%	₩11M ($8K)
2025-06-04	BUY	Market Buy	이상현 Sanghyun Lee	CEO	1.3K	₩3,400	-69.3%	₩4M ($3K)
2025-06-02	BUY	Market Buy	이상현 Sanghyun Lee	CEO	2.4K	₩2,985	-65.0%	₩7M ($5K)
2025-05-29	BUY	상속	이상현 Sanghyun Lee	CEO	1.7K	₩3,430	-69.5%	₩6M ($4K)
2025-03-26	BUY	신규선임	황운봉 Hwangunbong Peak	moving	31.5K	₩4,400	-76.3%	₩139M ($96K)
2021-07-30	BUY	Market Buy	이상현 Sanghyun Lee	CEO	8	₩20,900	-95.0%	₩167K ($116)
2021-07-30	BUY	Market Buy	이상현 Sanghyun Lee	CEO	34	₩20,900	-95.0%	₩711K ($493)
2021-07-30	BUY	Market Buy	이상현 Sanghyun Lee	CEO	85	₩20,900	-95.0%	₩2M ($1K)
2021-07-30	BUY	Market Buy	이상현 Sanghyun Lee	CEO	45	₩20,900	-95.0%	₩941K ($653)
2021-07-27	BUY	무상신주취득	이상현 Sanghyun Lee	CEO	1.3M	₩21,600	-95.2%	₩27.5B ($19.1M)

Frequently asked questions

Who has been buying Femtobiomed stock?: 1 distinct insiders have filed 14 disclosed insider purchases in Femtobiomed (327610), most recently on 2025-11-05. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Femtobiomed have?: Femtobiomed has 14 buy-side and 0 sell-side disclosures on record, covering ₩36M ($25K) in total reported value, spanning 2021-07-27 to 2025-11-05.
Do insider buys in Korean stocks predict returns?: Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

More on this data

Every trade listed above comes from an official regulatory disclosure. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.